MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Merkouris, M.
Right arrow Articles by Georgoussi, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Merkouris, M.
Right arrow Articles by Georgoussi, Z.

Identification of the critical domains of the delta-opioid receptor involved in G protein coupling using site-specific synthetic peptides

M Merkouris, I Dragatsis, G Megaritis, G Konidakis, C Zioudrou, G Milligan and Z Georgoussi

Institute of Biology, National Centre for Scientific Research Demokritos, Athens, Greece.

A large body of evidence implicates the second and third intracellular loops and the carboxyl-terminal portion of many G protein-coupled receptors as sites responsible for the interaction to G proteins. We synthesized a number of peptides from selected sites of the murine delta-opioid receptor and measured their ability to modify ligand- stimulated G protein activation and 3H agonist binding to the receptor. In membranes from Rat-1 fibroblasts transfected to express the murine delta-opioid receptor stably (clone D2 cells), the delta-opioid agonist [D-Ser2-Leu5-Thr6]enkephalin (DSLET) stimulated high affinity GTPase activity, which was inhibited by peptides that are derived from the proximal (i3.1) and the distal portions (i3.3) of the third intracellular loop with IC50 values of 15 +/- 5 and 50 +/- 4 microM, respectively. Peptides i3.1 and i3.3 inhibited DSLET-stimulated [35S]guanosine 5'-O-thiotriphosphate binding in the same membranes. However, a peptide designated i4, which was derived from a juxtamembranous region of the carboxyl-terminal tail of the delta- opioid receptor, failed to alter agonist-mediated high affinity GTPase activity or agonist-driven [35S]guanosine 5'-O-thiotriphosphate binding. Specific binding of [3H]DSLET to membrane preparations from clone D2 was reduced by peptides i3.1 and i4. Combinations of these peptides abolished detectable [3H]DSLET binding in the same membranes. Peptides i3.1 and i3.3 also destabilized the high affinity state of the receptor as assessed in 3H agonist binding on membranes from neuroblastoma X glioma (NG108-15) hybrid cells, which express the delta- opioid receptor endogenously; furthermore, delta-opioid receptor- stimulated GTPase activity in the same membranes was inhibited by peptides i3.1 and i3.3 but i4 was inactive. In contrast, peptides derived from the second intracellular loop (i2.1 and i2.2), an intermediate portion of the third intracellular loop (i3.2), and the extreme amino-terminal region of the receptor were without effect in these assays. These observations indicate that although peptides i3.1, i3.3, and i4 act via different mechanisms, they provide evidence that at least two sites of the third intracellular loop and part of the carboxyl-terminal tail of the delta-opioid receptor are important in the interaction between this receptor and cellular G proteins. Collectively, these results provide novel information about regions of the delta-opioid receptor that are involved in G protein coupling and high affinity agonist binding.

Volume 50, Issue 4, pp. 985-993, 10/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
E. Morou and Z. Georgoussi
Expression of the Third Intracellular Loop of the {delta}-Opioid Receptor Inhibits Signaling by Opioid Receptors and Other G Protein-Coupled Receptors
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1368 - 1379.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
C. Liu, G. Sandford, G. Fei, and J. Nicholas
G{alpha} Protein Selectivity Determinant Specified by a Viral Chemokine Receptor-Conserved Region in the C Tail of the Human Herpesvirus 8 G Protein-Coupled Receptor
J. Virol., March 1, 2004; 78(5): 2460 - 2471.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. Wang, H. H. Loh, and P.-Y. Law
The Intracellular Trafficking of Opioid Receptors Directed by Carboxyl Tail and a Di-leucine Motif in Neuro2A Cells
J. Biol. Chem., September 19, 2003; 278(38): 36848 - 36858.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
V. Chaipatikul, H. H. Loh, and P. Y. Law
Ligand-Selective Activation of {micro}-Opioid Receptor: Demonstrated with Deletion and Single Amino Acid Mutations of Third Intracellular Loop Domain
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 909 - 918.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
B. Cen, Y. Xiong, L. Ma, and G. Pei
Direct and Differential Interaction of {beta}-Arrestins with the Intracellular Domains of Different Opioid Receptors
Mol. Pharmacol., April 1, 2001; 59(4): 758 - 764.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
S. Mukhopadhyay, H. H. McIntosh, D. B. Houston, and A. C. Howlett
The CB1 Cannabinoid Receptor Juxtamembrane C-Terminal Peptide Confers Activation to Specific G proteins in Brain
Mol. Pharmacol., January 1, 2000; 57(1): 162 - 170.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
N. I. Tarasova, W. G. Rice, and C. J. Michejda
Inhibition of G-protein-coupled Receptor Function by Disruption of Transmembrane Domain Interactions
J. Biol. Chem., December 3, 1999; 274(49): 34911 - 34915.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
L. Brydon, F. Roka, L. Petit, P. de Coppet, M. Tissot, P. Barrett, P. J. Morgan, C. Nanoff, A. D. Strosberg, and R. Jockers
Dual Signaling of Human Mel1a Melatonin Receptors via Gi2, Gi3, and Gq/11 Proteins
Mol. Endocrinol., December 1, 1999; 13(12): 2025 - 2038.
[Abstract] [Full Text]


Home page
Pharmacol. Rev.Home page
R. M. Quock, T. H. Burkey, E. Varga, Y. Hosohata, K. Hosohata, S. M. Cowell, C. A. Slate, F. J. Ehlert, W. R. Roeske, and H. I. Yamamura
The delta -Opioid Receptor: Molecular Pharmacology, Signal Transduction, and the Determination of Drug Efficacy
Pharmacol. Rev., September 1, 1999; 51(3): 503 - 532.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. D. Smith, G. S. Oxford, and S. L. Milgram
Association of the D2 Dopamine Receptor Third Cytoplasmic Loop with Spinophilin, a Protein Phosphatase-1-interacting Protein
J. Biol. Chem., July 9, 1999; 274(28): 19894 - 19900.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. Kanwal, D. G. Lowe, and G. J. Trachte
Intracellular Fragments of the Natriuretic Peptide Receptor-C (NPR-C) Attenuate Dopamine Efflux
Endocrinology, March 1, 1999; 140(3): 1118 - 1124.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
K. Befort, D. Filliol, F. M. Decaillot, C. Gaveriaux-Ruff, M. R. Hoehe, and B. L. Kieffer
A Single Nucleotide Polymorphic Mutation in the Human {micro}-Opioid Receptor Severely Impairs Receptor Signaling
J. Biol. Chem., January 26, 2001; 276(5): 3130 - 3137.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1996 by the American Society for Pharmacology and Experimental Therapeutics